Abstract Regulatory T-cells play an important role in the regulation of the immune response and the mediation of dominant immunologic tolerance. We have previously shown that these cells are elevated in tumors and blood of patients with glioblastoma multiforme. Heme oxygenase-1, a rate-limiting enzyme in heme catabolism, has also been shown to accumulate during glioma progression and to play a critical role in FoxP3 mediated immune suppression. In this study, we investigated the correlation between FoxP3 and HO-1 expression in patients with various grades of astrocytoma (WHO grade II-IV). Using qualitative and quantitative reverse transcriptase-polymerase chain reaction and quantitative flow cytometry analyses, we analyzed FoxP3 and HO-1 expression in 19 patients with different grades of astrocytoma. We observed the highest level of FoxP3 expression in patients with grade IV tumors (11.54 ± 1.95%) vs. grade III (6.74 ± 0.19%) or grade II (2.53 ± 0.11%) (P < 0.05). Moreover, in grade IV tumors, the frequency of HO-1 mRNA expression in CD4 + CD25 + cells was 11.8 ± 2.45% vs. 7.42 ± 0.31% in grade III and 2.33 ± 0.12% in grade II. Tumor infiltrating Treg stained positively with anti-HO-1 antibody. The expression of HO-1 correlated with CD4 + CD25 + FoxP3 + infiltration (r = 0.966). Our results confirm that HO-1 expressing Treg accumulate during glioma progression. This study also suggests that HO-1 mRNA expression is linked to the induction of Foxp3 in CD4 + CD25 + glioma infiltrating Treg. These findings support the suppressive role played by regulatory T-cells in the growth of malignant brain tumors.
Introduction
Regulatory T-cells (also known as CD4 + CD25 + FoxP3 + , Treg) are a specialized subpopulation of T-cells that act to suppress activation of the immune system and thereby maintain immune system homeostasis and tolerance to self. There is increasing evidence for the existence of elevated numbers of regulatory T-cells in solid tumors and hematological malignancies [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . The presence of infiltrating Treg may be detrimental to the host defense against the tumor, while the presence of effector T lymphocytes, including CD8 + and nonregulatory CD4
+ helper T-cells may be beneficial. We have previously shown that there is an increase in the number of Treg both in tumor infiltrating lymphocytes as well as peripheral blood of patients with glioblastoma multiforme (GBM) [11] . Moreover, we have also shown that depletion of Treg prolongs the survival of mice with experimental brain tumors [12] .
Heme oxygenase (HO) is the rate-limiting enzyme in the catabolism of heme to biliverdin, carbon monoxide (CO), and free iron. To date, three isoforms of mammalian HO have been identified: HO-1, HO-2, and HO-3 [13] . HO-1 is inducible by a variety of stimuli, in particular, oxidative stress [14, 15] . HO-2 and HO-3 are constitutive iosozymes, found ubiquitously throughout the body, with high expression in brain and testes [16, 17] . Induction of HO-1 expression has been associated with neuroprotection during hyperthermia in glial cells [18] and during hypoxia [19] . HO-1 expression has also been observed in a wide range of experimental diseases of the rodent brain such as traumatic brain injury [20] , ischemia [21] , and human Alzheimer's disease [22] . In brain tumors, elevated HO-1 expression has been observed [23, 24] , and in at least one report, it would appear that HO-1 accumulates during oligodenodroglioma progression [25] .
The exact functional role of HO-1 expression is not fully understood in T-cells. However, growing evidence has shown that human Treg constitutively express HO-1 and that HO-1 inhibits T-cell proliferation [26] . Over-expression of HO-1 further renders T-cells resistant to Fas-mediated apoptosis [27] . Most recently, FoxP3, which encodes a forkhead/winged-helix transcription repressor specifically expressed in Treg, has been shown to induce HO-1 expression [28] . Taken together, these studies suggest that HO-1 may be an important effector of FoxP3-mediated immune suppression and an important target for further clinical development.
In the present study, we investigated the expression of HO-1 and Treg infiltration in various grades of human glioma. Both qualitative and quantitative reverse transcription polymerase chain reaction was used to demonstrate HO-1 and FoxP3 gene expression. Flow cytometry was used to quantify Treg infiltration. We report here for the first time that HO-1 and FoxP3 expression directly correlates with tumor grade in patients with malignant glioma.
Materials and methods

Patient samples
Resected specimens from 19 performed as a percentage of total CD3 + cells in TILs. Monoclonal antibody to HO-1 was from Stressgen Biotechnologies (Victoria, BC). These monoclonal antibodies were directly coupled to fluorescein isothiocyanate, phycoerythrin, or phycoerythrin-indotricarbocyanin. Antibodies were used at 5 lg/ml and staining was done in fluorescence-activated cell sorting (FACS) buffer on ice for 45 min. Surface marker expression on TIL cells was visualized with FACSCalibur TM (BD Biosciences) and was analyzed with FlowJo software (BD Biosciences). Tumor cells sorting without tumor infiltrating lymphocyte was done with a MoFlo cell sorter (Cytomation, Fort Collins, CO).
Semiquantitative RT-PCR and real-time PCR Total cellular RNA was isolated using RNeasy kit (Ambion Inc. Austin, TX) according to the manufacturer's protocol. Equivalent amounts of RNA were reverse-transcribed with the superscript II-RT kit (Invitrogen). The cDNA amplification was analyzed quantitatively by incorporation of SYBR Green (Applied Biosystems) into double stranded DNA. PCR was done in a total volume of 25 ll containing 1 ll cDNA template, 0.5 lM of each primer, and SYBR Green Master Mix (Applied Biosystems, Foster City, CA) under the following conditions: 15 min hot start at 95°C, 15 s denaturation at 95°C, 20 s annealing of primers at 54°C, and 15 s elongation at 72°C, for 32-35 cycles. Gene expression was analyzed with the ABI PRISM 7300 Sequence Detection Software version 1.9.1 (Applied Biosystems). Sample results were normalized by dividing the value of the unknown gene by the value of the endogenous reference gene encoding glyceraldehyde phosphate dehydrogenase (GAPDH). Quadruplicate reactions were done with all cDNA samples. We used the following primers (Invitrogen, Carlsbad, CA): HO-1 forward (5¢-ACT TTC AGA AGG GTC AGG TGT CC-3¢); HO-1 reverse (5¢-TTG AGC AGG AA G GCG GTC TTA G-3¢); Foxp3 forward (5¢-ATG CCT CCT CTT CTT CCT TGA-3¢); Foxp3 reverse (5¢-ATT GTG CCC TGC CCT TCT CA-3¢); GAPDH forward (5¢-GGC ATG GAC TGT GGT CAT GA-3¢), and GAPDH reverse (5¢-TGC ACC ACC AAC TGC TTA GC-3¢). HO-1 and Foxp3 mRNA levels were normalized to total CD3 + T-cells.
Statistical analysis
Statistical analysis was performed with StatView software (SAS). Differences in continuous variables between groups were tested by ANOVA with the Scheff ' F-test used as a post hoc test. Correlation was analyzed by multiple linear regression method. The observed differences were considered statistically significant if P was less than 0.05. All data are expressed as mean ± SEM.
Results
CD4 + CD25 + T-cell infiltration increases with tumor grade
The CD4 + CD25 + T-cells were gated via the forward and side scatter properties of TIL (Fig. 1A) . Analysis of TIL from glioma patients shows an increase in CD4 + CD25 + frequency with increasing tumor grade (Fig. 1B) + T-cells, using anti-HO-1 mAb. The frequency of HO-1 expression was analyzed in various tumor grades. The results, shown in Fig. 4A , illustrate progressive HO-1 expression in glioma infiltrating total CD4 + T-cells. The percentage of HO-1 expressing Treg was 31.1 ± 2.2% in grade IV tumors as compared to 12 ± 1.7% grade III tumors, and 7.78 ± 1.1% grade II tumors (P < 0.02). Furthermore, the induction of HO-1 expression was highest in CD4 + CD25 + FoxP3 + subset purified from patients with grade IV glioma (92.3 ± 1.75%) as compared to grade III (70.3 ± 2.3%) or grade II tumors (56.4 ± 2.86%) (P < 0.02) (Fig. 4B) .
The level of HO-1 directly correlates with FoxP3 expression
The expression of HO-1 was correlated with CD4 + CD25 + FoxP3 + infiltration. The coefficient of correlation between HO-1 mRNA and Foxp3 mRNA 
Discussion
Heme oxygenase-1, a key enzyme in heme catabolism, has recently been reported to be expressed by human brain tumors [23] , to represent a useful marker for angiogenesis in human gliomas [24] , and to accumulate during oligodendroglioma progression [25] . To date, only macrophages/microglia present in the stromal compartment of tumors have been shown to express HO-1 [24, 25] . In this study, we provide the first report to show that the expression of HO-1 and FoxP3 directly correlate with tumor grade. Moreover, we show that the expression of HO-1 is not unique to gliomas but is rather a function of Treg infiltration, and the increased infiltration of high-grade tumors with Treg is an important determinant of the immunosuppressive environment exhibited by malignant brain tumors. These are significant findings, which elucidate the mechanism of HO-1 induction and expression in human gliomas. HO-1 has an important role in rapid tumor growth because of its antioxidative and antiapoptotic effects [29, 30] . Indeed, there is convincing evidence that accumulation of HO-1 expressing macrophages in necrotic areas of malignant brain tumors contributes to neoplastic growth and tissue damage [24] . The expression of HO-1 is activated in response to various environmental insults, including hypoxia, heat shock, heavy metal toxicity, and UV light irradiation [31, 32] . Although the accumulation of HO-1 expressing Treg may be induced by irradiation and chemotherapy administered to the patients (Table 1) , our published findings of Treg infiltration even in newly diagnosed gliomas [11] would argue against this hypothesis. Indeed, even in the present study we did not detect any significant difference in Treg infiltration between newly diagnosed versus recurrent grade IV astrocytomas. As such, we propose that Treg progressively infiltrate gliomas at various stages of the disease. In turn, this leads to localized HO-1 expression. The expression of HO-1 by Treg along with local tissue hypoxia/re-oxygenation stimulates a number of cytokines, proteolytic enzymes, and inhibitors, which play key role in the angiogenesis cascade. Indeed, HO-1 mediated heme degradation is the primary mechanism for cellular carbon monoxide (CO) production, and reactive oxygen intermediates, including CO, induce angiogenesis in vitro and in vivo [33] . Most recent studies confirm that HO-1 is a useful marker for neovascularization of human gliomas [24] . The exact role of HO-1 expression is not fully understood in T-cells. However, growing evidence has shown that HO-1 and its byproduct, CO, suppress T-cell proliferation [34, 35] . The over-expression of HO-1 results in the inhibition of several immune effector functions and thus provides an explanation for stressinduced immunosuppression [36] . Moreover, human CD4 + CD25 + T-cell constitutively express HO-1 [26] . It would appear the FoxP3 induces HO-1 expression and the suppressive effect of Foxp3 is not observed in the presence of HO-1 siRNA [28] . These findings provide a compelling argument that human FoxP3 may be a crucial regulatory gene for the expression of HO-1 and that HO-1 is engaged in FoxP3 mediated immune suppression.
In conclusion, we have shown that (1) Treg progressively infiltrate gliomas with increasing tumor grade; and (2) the expression of HO-1 directly correlates with the expression of Foxp3, a marker of Treg. Although we are aware that the small number of patients with grade II and grade III tumor may limit these conclusions, the data provides a compelling argument for a more extensive investigation of HO-1 and FoxP3 expression in a larger number of patients. Our findings suggest that, at least in part, the expression of HO-1 by gliomas is dependent on the presence of CD4 blue is specific staining). Specifically, the induction of HO-1 expression was highest in CD4 + CD25 + FoxP3 + subset purified from patients with grade IV glioma (92.3 ± 1.75%) as compared to grade III (70.3 ± 2.3%) or grade II tumors (56.4 ± 2.86%) (P < 0.02) (Fig. 4B) . In contrast, there was no evidence of HO-1 expression in CD4 + CD25 -(data not shown) 
